The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives

Hannah Walgrave, Lujia Zhou, Bart De Strooper, Evgenia Salta

Research output: Contribution to journal/periodicalArticleScientificpeer-review

34 Downloads (Pure)


Multi-pathway approaches for the treatment of complex polygenic disorders are emerging as alternatives to classical monotarget therapies and microRNAs are of particular interest in that regard. MicroRNA research has come a long way from their initial discovery to the cumulative appreciation of their regulatory potential in healthy and diseased brain. However, systematic interrogation of putative therapeutic or toxic effects of microRNAs in (models of) Alzheimer's disease is currently missing and fundamental research findings are yet to be translated into clinical applications. Here, we review the literature to summarize the knowledge on microRNA regulation in Alzheimer's pathophysiology and to critically discuss whether and to what extent these increasing insights can be exploited for the development of microRNA-based therapeutics in the clinic.

Original languageEnglish
Pages (from-to)76
JournalMolecular Neurodegeneration
Issue number1
Publication statusPublished - 06 Nov 2021


Dive into the research topics of 'The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives'. Together they form a unique fingerprint.

Cite this